ADA Updates on Finerenone, SGLT2 Inhibitors, and Race-Based eGFR

ADA has made an interim change to its latest Standards of Medical Care, an update based on trial evidence and consensus about finerenone, SGLT2 inhibitors, and eGFR.
Medscape Medical News